Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.

Johnston L, Power M, Sloan P, Long A, Silmon A, Chaffey B, Lisgo AJ, Little L, Vercauteren E, Steiniche T, Meyer T, Simpson J.

J Clin Pathol. 2018 Apr;71(4):336-343. doi: 10.1136/jclinpath-2017-204629. Epub 2017 Sep 12.

2.

Comparative assessment of local tolerance of alcohols commonly used in alcohol-based hand rubs for hand hygiene.

Manche M, Foligné B, Sauty M, Platel A, Vercauteren E, Rauwel G, Catoire S, Ficheux H, Criquelion J, Nesslany F.

Toxicol In Vitro. 2017 Oct;44:142-153. doi: 10.1016/j.tiv.2017.07.004. Epub 2017 Jul 9.

PMID:
28700953
3.

Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis.

Vercauteren E, Gils A, Declerck PJ.

Semin Thromb Hemost. 2013 Jun;39(4):365-72. doi: 10.1055/s-0033-1334488. Epub 2013 Mar 2. Review.

PMID:
23457049
4.

Plasmin and the thrombin-thrombomodulin complex both contribute to thrombin-activatable fibrinolysis inhibitor activation in whole blood model thrombi.

Vercauteren E, Mutch NJ, Declerck PJ, Gils A.

J Thromb Haemost. 2013 Jan;11(1):190-2. doi: 10.1111/jth.12062. No abstract available.

5.

The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.

Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A.

J Thromb Haemost. 2012 Dec;10(12):2555-62. doi: 10.1111/jth.12036.

6.

Is there any need for a TAFI(a) inhibitor as thrombolytic drug?

Vercauteren E, Gils A.

Thromb Res. 2012 Oct;130(4):574-5. doi: 10.1016/j.thromres.2012.07.010. Epub 2012 Jul 26. No abstract available.

PMID:
22840781
7.

Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms.

Mishra N, Vercauteren E, Develter J, Bammens R, Declerck PJ, Gils A.

Thromb Haemost. 2011 Jul;106(1):90-101. doi: 10.1160/TH10-08-0546. Epub 2011 May 5.

PMID:
21544309
8.

Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model.

Vercauteren E, Emmerechts J, Peeters M, Hoylaerts MF, Declerck PJ, Gils A.

Blood. 2011 Apr 28;117(17):4615-22. doi: 10.1182/blood-2010-08-303677. Epub 2011 Feb 22.

PMID:
21343611
9.
11.

Survey of enterococcal susceptibility patterns in Belgium.

Vandamme P, Vercauteren E, Lammens C, Pensart N, Ieven M, Pot B, Leclercq R, Goossens H.

J Clin Microbiol. 1996 Oct;34(10):2572-6.

12.

Identification of a cytolytic protein in the coelomic fluid of Eisenia foetida earthworms.

Bilej M, Brys L, Beschin A, Lucas R, Vercauteren E, Hanusová R, De Baetselier P.

Immunol Lett. 1995 Feb;45(1-2):123-8.

PMID:
7622179
13.

TNF-alpha mediated selection of macrophage-resistant gene-regulatory tumor variants.

Remels L, Neirynck A, Brys L, Vercauteren E, De Baetselier P.

Clin Exp Metastasis. 1989 Sep-Oct;7(5):493-506.

PMID:
2473862
14.

Anti-micrococcus antibodies recognize an antigenic marker of confluent mouse lymphoid cell lines.

Grooten J, De Baetselier P, Vercauteren E, Hamers R.

Nature. 1980 Jun 5;285(5764):401-3. No abstract available.

PMID:
7383159

Supplemental Content

Loading ...
Support Center